PT - JOURNAL ARTICLE AU - DiMasi, Joseph A. AU - Dirks, Abigail AU - Smith, Zachary AU - Valentine, Sarah AU - Goldsack, Jennifer C. AU - Metcalfe, Thomas AU - Grewal, Upinder AU - Leyens, Lada AU - Conradi, Ute AU - Karlin, Daniel AU - Maloney, Lesley AU - Getz, Kenneth A. AU - Hartog, Bert TI - ASSESSING THE NET FINANCIAL BENEFITS OF EMPLOYING DIGITAL ENDPOINTS IN CLINICAL TRIALS AID - 10.1101/2024.03.07.24303937 DP - 2024 Jan 01 TA - medRxiv PG - 2024.03.07.24303937 4099 - http://medrxiv.org/content/early/2024/03/09/2024.03.07.24303937.short 4100 - http://medrxiv.org/content/early/2024/03/09/2024.03.07.24303937.full AB - Background In the last few decades developers of new drugs, biologics, and devices have increasingly leveraged digital health technologies (DHTs) to assess clinical trial digital endpoints. To our knowledge, a comprehensive assessment of the financial net benefits of digital endpoints in clinical trials has not been conducted.Data and Methods We obtained data from the Digital Medicine Society (DiMe) Library of Digital Endpoints and the U.S. clinical trials registry, ClinicalTrials.gov. The benefit metrics are changes in trial phase duration and enrollment associated with the use of digital endpoints. The cost metric was obtained from an industry survey of the costs of including digital endpoints in clinical trials. We developed an expected net present value (eNPV) model of the cash flows for new drug development and commercialization to assess financial value. The value measure is the increment in eNPV that occurs when digital endpoints are employed. We also calculated a return on investment (ROI) as the ratio of the estimated increment in eNPV to the mean digital endpoint implementation cost.Results For phase 2 trials, the increase in eNPV varied from $2.2 million to $3.3 million, with ROIs between 32% to 48% per indication. The net benefits were substantially higher for phase 3 trials, with the increase in eNPV varying from $27 million to $48 million, with ROIs that were four to seven times the investment.Conclusions The use of digital endpoints in clinical trials can provide substantial extra value to sponsors developing new drugs, with high ROIs.Competing Interest StatementJD, ZS, AD, and KG have nothing to disclose. JG and SV are employees of DiMe. TM, UG, LL, CU, DK, LM, and BH are employees of pharmaceutical companies.Funding StatementThis research was supported in part by a grant from Bayer, Johnson & Johnson, MindMed, and Roche to the Tufts Center for the Study of Drug DevelopmentAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced are available online at: https://aact.ctti-clinicaltrials.org/ https://dimesociety.org/get-involved/library-of-digital-endpoints/